In order to be eligible for the drug, patients must have NTRK fusions, which may be determined via various tests including NGS and FISH.
In development for several years, PORTIN is now being deployed as a single point of reference for all genotype and phenotype data at Bayer's research sites.
The partners have been working together since 2013 to use cancer and cardiovascular genomics for drug discovery.
The Boston-based synthetic biology company will use the proceeds to grow Bioworks3, its new organism foundry, and to expand into new markets.
Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.
Both deals should advance Ginkgo's custom microbe business as it expands into consumer goods markets such as cosmetics, nutrition, and food.
Companion diagnostics developed under the deal will be based on RNAscope and immunohistochemistry technology.
The deal gives Bayer access to the T2 Magnetic Resonance technology for drug discovery and biomarker research in certain hemostasis programs.
The deal with ERS Genomics, a commercialization vehicle for Emmanuelle Charpentier's patents, gives the Bayer LifeScience Center access to CRISPR/Cas9 genome editing.
The company's Avatar platform cultures and propagates a variety of cell types in an in vivo-like environment to yield more accurate and relevant molecular analyses.
Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.
A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.
Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.
In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.